Coca-Cola looks like a short at about 25x forward earnings for a business growing revenue slower than nominal GDP. All of its recent earnings growth has come from cost efficiencies, and it should face huge headwinds from the appetite-suppressing drugs people are taking to stop eating. x.com 

Coca-Cola's retained earnings do little for shareholders when management does not distribute much of the growth. At 27 times earnings, a 2.3% yield with no expected large dividend hikes, special dividend or meaningful buybacks makes look-through earnings a poor basis for the price: EPS rose about $1 in five years while dividends rose only 52 cents. x.com  x.com  x.com  x.com 

Coca-Cola's business is healthy, but its headline quarter overstates it, so the stance is bullish-neutral. Global volume rose 5%, free cash flow hit $6.9B year to date, and the dividend is covered at about 72% of free cash flow. But EPS grew 16% while currency-neutral comparable EPS grew 9%, underlying margin expansion was 24bp rather than about 90, and Asia Pacific price/mix fell 9% to defend shelf space. The raised 9-10% EPS growth guide includes about 3 points of currency tailwind. x.com 

Coca-Cola's valuation is no longer compelling despite strong operational execution. Shares trade at about 26.7 times earnings versus a historical average of 22.3, so much of the near-term optimism is priced in. Continued earnings growth can support the premium, but the margin of safety is considerably smaller. x.com 

Coca-Cola looks like a great funding short, since nothing makes it immune to the risks that battered its staples peers. GLP-1 drugs, store brands, new entrants and supply-chain inflation should hit it too, and non-sugar drinks only slow the U.S. decline, though international has held up better. About 2% revenue growth is thin support for 25x earnings while peers sit at 2008 valuations; it could fall to 15x unless the other staples rebound dramatically. x.com  x.com  x.com  x.com  x.com  x.com  x.com  … Show more

Coca-Cola may be the best defensive stock on the planet, with the simplest business model and a brand known everywhere from New York City to tiny villages in Asia. x.com 

Coca-Cola's safe-haven premium has gone too far. It trades at more than double Ferrari's price-to-free-cash-flow multiple while having the same EBITDA margins and nearly half the expected growth rate. x.com 

PepsiCo's valuation discount to Coca-Cola doesn't make sense: it trades at 17.75x earnings versus Coca-Cola's 26.70x, whatever one thinks of their sodas. x.com 

Coca-Cola is the ultimate safe haven, a holding that stabilizes and protects a portfolio. Since 2008 the best spot to add has been at or under the 200-week moving average; the test of that level at $60 in November 2024 signaled value with a margin of safety. Shares have since reached $84, a 39% climb in 20 months, plus a 2.5% dividend. x.com 

PepsiCo's forecast for another year of just 3% growth leaves it nowhere close to cheap. It trades at 16 times 2027 earnings. x.com